107株鲍曼不动杆菌感染临床资料与耐药性分析

目的：对鲍曼不动杆菌感染的临床特征和耐药性进行分析，为临床诊治提供参考。方法：对2005年1月～2006年6月我院临床分离的共107株鲍曼不动杆菌通过琼脂对倍稀释法进行MIC测定；同时对相应的临床病例进行回顾性分析。结果：107株鲍曼不动杆菌大多分离自痰液，主要来自于ICU病房；且91．59％的患者同时存在2种以上基础疾病。鲍曼不动杆菌对氨曲南耐药率最高，为89．72％，依次是头孢西丁（87．85％），头孢哌酮（76．64％）、哌拉西林（69．16％）、头孢噻肟（65．42％）、环丙沙星（65．42％）、阿米卡星（56．07％）、头孢他定（55．14％）等。结论：我院鲍曼不动杆菌耐药情况严重，治疗首选碳青霉烯类抗生素，其次可选用头孢吡肟、头孢哌酮／舒巴坦。

Clinical and Bactend Resister mdysis of 107 stochits Acinetobacter Baumannii

Objective： To analysis the clinical and resistance characteristics in isolates of Acinetobacter baumannii, to provide evidence of clinical therapy. Methods：One hundred and seven Acinetobacter baumannii strains were isolated from clinical specimens in West China Hospital from January 2005 to June 2006. The MICs of 12 common antimicrobial agents were determined by 2-fold agar dilution method followed by NCCLS recommendations. The 107 clinical cases were respectively analyzed retrospectively. Results： The majority of these resistant strains were isolated from sputum, and distributed in ICUs. 91.59% of patients with Acinetobacter baumannii suffered from two and more underlying diseases. The resistanet rates of 107 strains to Aztreonam, Cefoxitin, Cefeperazone, Piperacillin, Cefotaxime, Ciprofloxacin, Amikacin and Ceftazidime is 89.72% ,87.85%,76.64%,69.16%,65.42%,65.42%,56.07%,55.14%,respectively. Conclusion： There were many Acinetobacter baumannii to multiplex antimicrobial angents in our hospital. We use Imipenem Fefepime and Cefeperazone-sulbactam to therapy.